End-to-end automated manufacturing of low-seed CAR-T cells
Sponsor
The pathway to commercial success requires viewing commercial readiness through several lenses, including scalability, process development and optimization, cost and labor management, and GMP compliance.
For example, in CAR-T cell production, the upstream process must allow for a broad dynamic range in terms of cell seeding density - for example, to cater for both pediatric and adult dosages. A detailed investigation into the expansion of genetically modified CAR-T cells on the Quantum Flex Cell Expansion System was recently completed as part of a strategic collaboration between BioCentriq and Terumo Blood and Cell Technologies. This presentation not only details the technical results of this study, but also the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site.
Join this webinar to learn more about:
- Data describing cell expansion kinetics of CAR-T cells and deep phenotypic characterization
- Insights into the critical factors involved in the rapid technology transfer of an end-to-end manufacturing protocol to a contracted site
- Results of cell killing assays and cytokine re-stimulation responses
SPEAKERS
You might also like
Development of an automated AAV capsid titer assay on a high-throughput platform
Quickly and accurately measure key analytical attributes of viral vectors with macro mass photometry
Extracellular vesicles: setting-up the path to IND with advanced characterization packages
Optimizing bioprocess purification: effective nucleic acid removal in high salt environments
